LBO — BAYLOR MEDICAL CENTER-GRAPEVINE
IRR: 18.6% | MOIC: 2.35x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
18.6%
IRR
2.35x
MOIC
$296.9M
Entry EV
$483.3M
Exit EV
$152.8M
Equity Invested
Sources & Uses
S&UTotal · $296.9M| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $115.3M | 38.8% | |
| Sub Debt | $28.8M | 9.7% | |
| Equity | $152.8M | 51.5% | |
| Enterprise Value | $288.2M | 97.1% | |
| Transaction Fees | $8.6M | 2.9% | |
| Total Uses | $296.9M | 100.0% |
Interpretation
INTAt 2.35x MOIC and 18.6% IRR over 5 years, this deal meets the 15-20% range — acceptable with operational upside.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $46.0M |
| Exit Ev | $483.3M |
| Net Debt At Exit | $124.8M |
| Equity At Exit | $358.5M |
| Equity Invested | $152.8M |
| Total Value Created | $205.8M |
| Value From Growth | $180.6M |
| Value From Multiple | $14.4M |
| Value From Deleveraging | $19.3M |